LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Akciju saraksts・Myriad Genetics Inc

Myriad Genetics Inc

Slēgts

SektorsVeselības aprūpe

4.01 -5.65

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.92

Max

4.22

Galvenie mērījumi
By Trading Economics
Ienākumi	-26M -34M
Pārdošana	-9.4M 200M
EPS	-0.09
Peļņas marža	-17.016
Darbinieki	2,700
EBITDA	43M -18M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+90.84% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-106M 361M
Iepriekšējā atvēršanas cena	9.66
Iepriekšējā slēgšanas cena	4.01

Ziņu noskaņojums

By Acuity

57%

43%

283 / 344 Rangs Healthcare

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. maijs 23:08 UTC

Iegādes, apvienošanās, pārņemšana

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

2026. g. 29. maijs 23:06 UTC

Iegādes, apvienošanās, pārņemšana

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

2026. g. 29. maijs 20:53 UTC

Peļņas

Oil Declines Lift Stocks to Fresh Records -- WSJ

2026. g. 29. maijs 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 29. maijs 20:33 UTC

Tirgus saruna

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

2026. g. 29. maijs 20:11 UTC

Peļņas

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026. g. 29. maijs 19:47 UTC

Peļņas

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

2026. g. 29. maijs 19:36 UTC

Tirgus saruna

U.S. Natural Gas Futures End Month With Gains -- Market Talk

2026. g. 29. maijs 19:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 29. maijs 19:34 UTC

Tirgus saruna

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

2026. g. 29. maijs 19:22 UTC

Tirgus saruna

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

2026. g. 29. maijs 19:05 UTC

Iegādes, apvienošanās, pārņemšana

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

2026. g. 29. maijs 18:19 UTC

Tirgus saruna

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

2026. g. 29. maijs 18:12 UTC

Iegādes, apvienošanās, pārņemšana

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

2026. g. 29. maijs 18:11 UTC

Tirgus saruna

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

2026. g. 29. maijs 18:10 UTC

Tirgus saruna

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

2026. g. 29. maijs 17:55 UTC

Peļņas

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026. g. 29. maijs 17:55 UTC

Tirgus saruna

NEAR Protocol Nearly Doubles in May -- Market Talk

2026. g. 29. maijs 17:38 UTC

Tirgus saruna

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

2026. g. 29. maijs 17:00 UTC

Peļņas

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

2026. g. 29. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 29. maijs 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 29. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 29. maijs 16:02 UTC

Tirgus saruna

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

2026. g. 29. maijs 15:55 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 29. maijs 15:55 UTC

Tirgus saruna

Cryptocurrencies Appear Detached From Stocks -- Market Talk

2026. g. 29. maijs 15:50 UTC

Iegādes, apvienošanās, pārņemšana

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

2026. g. 29. maijs 15:50 UTC

Iegādes, apvienošanās, pārņemšana

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

2026. g. 29. maijs 15:40 UTC

Tirgus saruna

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

2026. g. 29. maijs 15:20 UTC

Tirgus saruna

Canada's Economy Not Looking All That Bright -- Market Talk

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

90.84% augšup

Prognoze 12 mēnešiem

Vidējais 7.5 USD 90.84%

Augstākais 10 USD

Zemākais 5.5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

283 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.